 Shares of ProKidney Corp. PROK, 9.57 rallied about 29 in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the companys investigational renal autologous cell therapy treatment can delay the need for dialysis in some patients with chronic kidney disease. The study was published Jan. 4 in the journal Blood Purification; the company issued a news release about the study on Tuesday. 